$EXAM (ExamWorks Group, Inc.)

$EXAM {{ '2016-01-11T15:23:31+0000' | timeago}} • Announcement

$EXAM said it has acquired ABI Document Support Services Inc. (ABI) for an all-cash purchase price of $62MM. The company stated that it funded the acquisition with cash on hand and borrowings under its existing senior secured revolving credit facility. ABI is expected to generate annual revenues of approx. $40MM in 2016.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$MRK {{ '2018-01-09T20:27:32+0000' | timeago}} • Announcement

Pharma company $MRK said the FDA has granted 'Breakthrough Therapy Designation' for Lenvima, a multiple receptor tyrosine kinase inhibitor developed by Eisai in combination with Merck's anti-PD-1 therapy Keytruda for the treatment of renal cell carcinoma. The FDA action was based on the results of a multi-center study conducted in US and Europe.

$MRK {{ '2018-01-09T18:45:44+0000' | timeago}} • Announcement

Merck today announced that it has received Breakthrough Therapy Designation from FDA for LENVIMA and KEYTRUDA. The combination therapy (LENVIMA & KEYTRUDA) is being jointly developed by Eisai and $MRK for treating patients with advanced and/or metastatic renal cell carcinoma. In 2017, approx. 63,990 new cases were estimated to have occurred in US.

$MCK {{ '2018-01-03T15:10:09+0000' | timeago}} • Announcement

$MCK announced that it has completed the acquisition of RxCrossroads.

$MRK {{ '2018-01-02T20:34:14+0000' | timeago}} • Announcement

Merck announced today that Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its cancer drug KEYTRUDA for treating patients with Urothelial Carcinoma, a type of bladder cancer. This approval helps $MRK to market KEYTRUDA for 4 types of cancer in Japan. The company plans to market KEYTRUDA in partnership with Taiho Pharmaceuticals.

$MNK {{ '2017-12-26T12:28:16+0000' | timeago}} • Announcement

$MNK agreed to buy $SCMP, including its commercial and development assets, for about $1.2Bil. $MNK's subsidiary Sun Acquisition Co. will begin a cash tender offer for $18 per share. $MNK expects accretion from acquisition to adjusted EPS of at least $0.30 in 2018 and at least double that amount in 2019, assuming 1Q18 close.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$LCI {{ '2017-12-21T16:48:17+0000' | timeago}} • Announcement

$LCI BoD named Timothy C. Crew as the company's chief executive officer, effective January 2, 2018. He has over 25 years of experience in the generic and branded pharmaceutical industries. Crew will succeed Arthur Bedrosian, the current CEO.

$HUM {{ '2017-12-19T15:27:46+0000' | timeago}} • Announcement

$HUM signed a definitive agreement to acquire a 40% minority interest in the Kindred at Home Division of $KND for an estimated cash consideration of approximately $800MM. Humana does not anticipate a material impact to earnings in 2017 from this pending transaction.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

$KND {{ '2017-12-19T13:44:51+0000' | timeago}} • Announcement

$KND's BoD approved a definitive agreement whereby it will be acquired by a consortium of three companies: TPG Capital, Welsh, Carson, Anderson & Stowe and $HUM for about $4.1Bil in cash including the assumption or repayment of net debt. The transaction is expected to close during the summer of 2018.

$MCK {{ '2017-12-18T14:35:21+0000' | timeago}} • Announcement

$MCK CFO James Beer will be leaving the company. Britt Vitalone will be appointed EVP and CFO of the company, effective Jan. 1, 2018. In addition, $MCK reaffirmed its adjusted EPS outlook of $11.80-12.50 for FY18.

$MCK {{ '2017-12-18T14:33:36+0000' | timeago}} • Announcement

$MCK said James Beer, EVP and CFO, will be leaving the company to pursue a new opportunity. Britt Vitalone, SVP and CFO, U.S. Pharmaceutical and McKesson Specialty Health, will be appointed EVP and CFO of McKesson, effective Jan. 1, 2018. Beer will assist in a transition period into early 2018.

$ESRX {{ '2017-12-14T15:34:37+0000' | timeago}} • Announcement

$ESRX's enterprise value initiative is currently estimated to cost approx. $600-650MM and to deliver cumulative savings of nearly $1.2Bil by 2021. The company's 2018 full-year guidance includes an estimated contribution of $65-75MM in expense savings affecting the Core and consolidated businesses.

$ESRX {{ '2017-12-14T15:34:20+0000' | timeago}} • Announcement

For 2018, $ESRX expects adjusted diluted EPS to be $7.67-7.87, up 9-12% from the midpoint of the updated 2017 adjusted EPS guidance range. The company expects consolidated revenue to be $99-102Bil and Core revenue to be $80.5-83Bil. Total adjusted claims for the consolidated business is expected to be $1.34-1.39Bil.

$ESRX {{ '2017-12-14T15:34:05+0000' | timeago}} • Announcement

$ESRX expects full-year 2017 total adjusted claims for its Core business to be 1.15-1.17Bil, which is flat over Core 2016 total adjusted claims at the midpoint of the range. The company expects Core 2017 adjusted EBITDA guidance to be $4.91-4.97Bil, representing growth of 3% over Core 2016 adjusted EBITDA results at the midpoint of the range.

Recent Transcripts

RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
PRSC (Providence Service Corp.)
Wednesday, November 8 2017 - 1:00pm
KND (Kindred Healthcare Inc.)
Tuesday, November 7 2017 - 2:00pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, November 7 2017 - 1:30pm
LCI (Lannett Company, Inc.)
Monday, November 6 2017 - 9:30pm
LHCG (LHC Group, Inc.)
Monday, November 6 2017 - 4:00pm
CVS (CVS Health Corporation)
Monday, November 6 2017 - 1:30pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
CHE (Chemed Corp.)
Friday, October 27 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Friday, October 27 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, October 26 2017 - 12:00pm
LH (Laboratory Corp. of America Holdings)
Wednesday, October 25 2017 - 1:00pm
ESRX (Express Scripts Holding Company)
Wednesday, October 25 2017 - 12:30pm
PETS (PetMed Express, Inc.)
Monday, October 23 2017 - 12:30pm
RAD (Rite Aid Corporation)
Thursday, September 28 2017 - 12:30pm
LCI (Lannett Company, Inc.)
Wednesday, August 23 2017 - 8:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
PRSC (Providence Service Corp.)
Wednesday, August 9 2017 - 12:00pm
CVS (CVS Health Corporation)
Tuesday, August 8 2017 - 12:30pm

AlphaGraphics you may like